Oncimmune Holdings plc

LSE ONC.L

Oncimmune Holdings plc Net Income Margin for the year ending August 31, 2023: 356.25%

Oncimmune Holdings plc Net Income Margin is 356.25% for the year ending August 31, 2023, a 244.53% change year over year. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Oncimmune Holdings plc Net Income Margin for the year ending May 31, 2022 was -246.49%, a -98.23% change year over year.
Oncimmune Holdings plc Net Income Margin for the year ending May 31, 2021 was -124.34%, a 92.52% change year over year.
Oncimmune Holdings plc Net Income Margin for the year ending May 31, 2020 was -1,661.89%, a 64.53% change year over year.
Oncimmune Holdings plc Net Income Margin for the year ending May 31, 2019 was -4,685.38%, a -78.21% change year over year.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

LSE: ONC.L

Oncimmune Holdings plc

CEO	Mr. Martin John Gouldstone
IPO Date	May 18, 2016
Location	United Kingdom
Headquarters	MediCity
Employees	38
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Oncimmune Holdings plc develops and commercializes technologies that enable cancer diagnosis in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, a immunodiagnostic test for detecting and identifying lung cancer. The company also develops SeroTag, a platform that is used to discover and validate biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Nottingham, the United Kingdom.

Key trends

Past 5 years